Form 8-K Zymeworks Inc. For: May 27
Exhibit 99.1
Zymeworks Announces Participation in Upcoming Investor Conference
Vancouver, Canada and Seattle, Washington (May 27, 2022) Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:
| Jefferies Healthcare Conference. Zymeworks will participate in one-on-one meetings on June 8th 9th and will present on June 8th at 9:30 a.m. ET in New York, NY. |
The presentation will be available on Zymeworks website at http://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks second clinical candidate, ZW49, is a novel bispecific HER2-targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks proprietary ZymeLink linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.
Contacts:
Investor Inquiries:
Jack Spinks
(604) 678-1388
Media Inquiries:
Diana Papove
(604) 678-1388
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zymeworks (ZYME) Appoints Neil Gallagher to its Board
- OKX Ventures Report: Crypto and AI Convergence Will Lead to New Applications and Innovations in Digital Infrastructure
- Zymeworks Announces Participation in Upcoming Investor Conferences
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!